Meta-analysis of the Relationship Between Plasma Homocysteine Levels and Carbamazepine Monotherapy in Patients with Epilepsy

Abstract

Background: Numerous studies have shown that long- term treatment with anticonvulsants may be an important risk factor for the onset of atherosclerosis, or worsening of its symptoms. Context: The present study aimed at investigating the relationship between carbamazepine (CBZ) monotherapy and plasma homocysteine (Hcy) levels in patients with epilepsy. Evidence Acquisition: Studies concerning homocysteine levels in carbamazepine monotherapy patients with epilepsy, which were published in VIP, Wanfang, CNKI, Cochrance Library, PubMed, Web of Science, and EMBASE, were included in March 2016. The quality of the controlled clinical trials (CCT) selected for this study was assessed using the Newcastle-Ottawa scale (NOS), and the relevant data of the included studies were extracted through RevMan5.2 software. Results: In this meta-analysis, 22 eligible studies were enrolled including 9 Chinese and 13 English studies. The study included a total of 1604 cases including 575 cases of patient group and 1029 control group cases. Results of the meta-analysis showed that plasma homocysteine level in patients with epilepsy with long- term treatment of CBZ was significantly higher than that in the healthy control group [SMD = 1.55, 95% CI: [1.09, 2.01], P |Z|= 0.091 > 0.05 (no statistical significance), suggesting no significant publication bias in the study. Loss factor of safety (Nfs) 0.05 equaled 7269.16 (P = 0.05), meaning that addition of about 7269 negative results were required to overthrow the conclusion of this study. Conclusions: The seizures significantly increased plasma homocysteine levels in the patients, thus it is appropriate to add folic acid, vitamin B12, and vitamin B6 to reduce the seizures. Moreover, homocysteine may be beneficial for those patients with epilepsy who take carbamazepine.